AU2003298176A1 - Method to treat conditions associated with insulin signaling dysregulation - Google Patents

Method to treat conditions associated with insulin signaling dysregulation

Info

Publication number
AU2003298176A1
AU2003298176A1 AU2003298176A AU2003298176A AU2003298176A1 AU 2003298176 A1 AU2003298176 A1 AU 2003298176A1 AU 2003298176 A AU2003298176 A AU 2003298176A AU 2003298176 A AU2003298176 A AU 2003298176A AU 2003298176 A1 AU2003298176 A1 AU 2003298176A1
Authority
AU
Australia
Prior art keywords
conditions associated
treat conditions
insulin signaling
signaling dysregulation
dysregulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003298176A
Inventor
Hao Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003298176A1 publication Critical patent/AU2003298176A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/033Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0337Genetically modified Arthropods
    • A01K67/0339Genetically modified insects, e.g. Drosophila melanogaster, medfly
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Insects & Arthropods (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003298176A 2002-12-12 2003-12-11 Method to treat conditions associated with insulin signaling dysregulation Abandoned AU2003298176A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43285402P 2002-12-12 2002-12-12
US60/432,854 2002-12-12
PCT/EP2003/014078 WO2004052094A1 (en) 2002-12-12 2003-12-11 Method to treat conditions associated with insulin signaling dysregulation

Publications (1)

Publication Number Publication Date
AU2003298176A1 true AU2003298176A1 (en) 2004-06-30

Family

ID=32508000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003298176A Abandoned AU2003298176A1 (en) 2002-12-12 2003-12-11 Method to treat conditions associated with insulin signaling dysregulation

Country Status (4)

Country Link
EP (1) EP1571903A1 (en)
JP (1) JP2006509795A (en)
AU (1) AU2003298176A1 (en)
WO (1) WO2004052094A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503677A (en) * 1999-06-22 2003-01-28 ウニベルジテート チューリッヒ In vivo insect model system for type 2 diabetes
JPWO2002043760A1 (en) * 2000-12-01 2004-04-02 住友製薬株式会社 Sugar metabolism activator

Also Published As

Publication number Publication date
JP2006509795A (en) 2006-03-23
EP1571903A1 (en) 2005-09-14
WO2004052094A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
EP1720993B8 (en) Method for producing l-threonine using bacteria belonging to the genus escherichia
AU2003288050A1 (en) Selective stimulation with selective water reduction
AU2003220394A1 (en) Syringe with integral safety system
AU2003220076A1 (en) System to improve after-treatment regeneration
AUPS005002A0 (en) Improvements relating to walling methods
AU2003228796A1 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
HK1085747A1 (en) Methods for refining concentrated enzyme solutions
AU2003294487A1 (en) Ballast water treatment system
AUPS328002A0 (en) Water treatment
AU2003296878A1 (en) Methods to administer epothilone d
AU2003247520A1 (en) Recycled irrigation water treatment system
AUPS239302A0 (en) Improvements to tow-bars
AU2002241277A1 (en) Functional plant, promoter to be used for producing the functional plant and method of using the same
AU2002236116A1 (en) Method to treat soapy wastewater
AU2003298176A1 (en) Method to treat conditions associated with insulin signaling dysregulation
AUPS334902A0 (en) Purification method
AU2002951011A0 (en) Water treatment process
AU2003255758A1 (en) Improvements relating to water treatment
AU2003299652A1 (en) Methods for treating diabetes
AU2003223295A1 (en) Process and intermediates to substituted imidazopyrimidines
AU2002100158A4 (en) Water injection method
AP2005003377A0 (en) Method of dermal protection.
AU2002349868A1 (en) Easily mountable fence, due to the method used
AU2003273258A1 (en) Process to prepare psorospermin
AU2003203405A1 (en) Fireproofing treatment method using water glass

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase